Follow-up services for patients with localised cutaneous melanoma are widely discussed but there is no international consensus. Our aim was to discuss frequency and duration of follow-up, type of health professional involved, optimum intensity of routine investigation, and patients' satisfaction with follow-up. Searches of the published work were directed at publications between January, 1985, and February, 2004 on recurrences, subsequent primary melanoma, routine tests, and patients' satisfaction. In a selection of 72 articles, 2142 (6.6%) recurrences were reported, 62% of which were detected by the patients themselves. 2.6% of patients developed a subsequent primary melanoma. Most investigators do not support high-intensity routine follow...
Background Despite current guidelines, there is uncertainty about the required duration and frequenc...
Background: The purpose, frequency and content of follow-up (FU) visits have been widely debated for...
Post-treatment follow-up for patients with American Joint Committee on Cancer (AJCC) stage I/II mela...
Follow-up services for patients with localised cutaneous melanoma are widely discussed but there is ...
Introduction: Follow-up guidelines for melanoma greatly differ in the methods of screening for recur...
The aim of followup programs for patients diagnosed with melanoma is early detection of local, regio...
Background: The value of follow-up surveillance for patients with cutaneous melanoma remains uncerta...
Background: The value of follow-up surveillance for patients with cutaneous melanoma remains uncerta...
The primary goal of follow-up examinations in cutaneous melanoma is to detect development of second ...
Surgical treatment of primary cutaneous melanoma has significantly changed in the last decades. Tumo...
AIMS: Information of prognosis for patients with cutaneous melanoma is sparse and controversial. An ...
BACKGROUND: Patients treated for melanoma are advised to have lifelong full body skin examinations....
Background: The purpose, frequency and content of follow-up (FU) visits have been widely debated for...
Health care providers and their patients jointly participate in melanoma prevention, surveillance, d...
Abstract Background Patients may decide to undertake shared care with a general practitioner (GP) du...
Background Despite current guidelines, there is uncertainty about the required duration and frequenc...
Background: The purpose, frequency and content of follow-up (FU) visits have been widely debated for...
Post-treatment follow-up for patients with American Joint Committee on Cancer (AJCC) stage I/II mela...
Follow-up services for patients with localised cutaneous melanoma are widely discussed but there is ...
Introduction: Follow-up guidelines for melanoma greatly differ in the methods of screening for recur...
The aim of followup programs for patients diagnosed with melanoma is early detection of local, regio...
Background: The value of follow-up surveillance for patients with cutaneous melanoma remains uncerta...
Background: The value of follow-up surveillance for patients with cutaneous melanoma remains uncerta...
The primary goal of follow-up examinations in cutaneous melanoma is to detect development of second ...
Surgical treatment of primary cutaneous melanoma has significantly changed in the last decades. Tumo...
AIMS: Information of prognosis for patients with cutaneous melanoma is sparse and controversial. An ...
BACKGROUND: Patients treated for melanoma are advised to have lifelong full body skin examinations....
Background: The purpose, frequency and content of follow-up (FU) visits have been widely debated for...
Health care providers and their patients jointly participate in melanoma prevention, surveillance, d...
Abstract Background Patients may decide to undertake shared care with a general practitioner (GP) du...
Background Despite current guidelines, there is uncertainty about the required duration and frequenc...
Background: The purpose, frequency and content of follow-up (FU) visits have been widely debated for...
Post-treatment follow-up for patients with American Joint Committee on Cancer (AJCC) stage I/II mela...